Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.
about
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyNanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugsBypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia TherapyOvercoming drug efflux-based multidrug resistance in cancer with nanotechnologySmall and Innovative Molecules as New Strategy to Revert MDRPersistent pharmacokinetic challenges to pediatric drug developmentTreatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsPharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsP-glycoprotein-dependent trafficking of nanoparticle-drug conjugatesSize matters: gold nanoparticles in targeted cancer drug delivery.Characterization of the host-guest complex of a curcumin analog with β-cyclodextrin and β-cyclodextrin-gemini surfactant and evaluation of its anticancer activity.HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo.Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex.P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cellsCharacterising lipid lipolysis and its implication in lipid-based formulation development.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.Formulation strategies for drug delivery of tacrolimus: An overview.Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions.Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals.Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.Control of targeting ligand display by pH-responsive polymers on gold nanoparticles mediates selective entry into cancer cells.Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.Excipient Nanoemulsions for Improving Oral Bioavailability of Bioactives.Review and analysis of FDA approved drugs using lipid-based formulations.SNEDDS Containing Poorly Water Soluble Cinnarizine; Development and in Vitro Characterization of Dispersion, Digestion and Solubilization.Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies.Enhancement of intestinal absorption of 2-methyl cytidine prodrugs.Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems.Influence of the nanocomposite MgAl-HTlc on gastric absorption of drugs: in vitro and ex vivo studies.Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems.Bioavailability of Cinnarizine in Dogs: Effect of SNEDDS Loading Level and Correlation with Cinnarizine Solubilization During In Vitro Lipolysis
P2860
Q26745710-E023BF57-C256-4A83-BDFF-6264971B8A0AQ26774831-6F2C3409-AE88-484A-8FB3-BB3399626042Q26780502-3A3EAF62-4F33-467D-A8E7-2DB72F66D5E2Q26849264-2D158F72-21CA-4671-A72F-2EC6EB8F86BEQ27012455-B897DCDD-1A1B-41F8-ABF3-6BC1DEF895B7Q27023912-1095880C-2C27-4901-A481-1EB96E52DF56Q27025606-20786C1B-4BC5-489F-B984-DABD0A0C18E9Q28084784-895FC100-48DB-4253-B3D8-623226B70524Q34062299-15AEA6AE-AB53-42DF-AFC7-17BADA7B0117Q34290392-99831B7F-F1EF-401D-A68C-D84F5E5CA4FBQ34982395-FCFAC4DC-A671-4259-ACA4-B8A2101C918AQ35091852-B7981E9B-A67A-4176-AC62-DD224AC8A1CCQ35677172-F40FBC78-5A77-4A3E-911E-2E0A4569F02FQ36174338-508EB68E-8CC3-4B36-9264-AFA7745AD3A9Q36331543-DA0C005A-C94C-4ECB-95B7-6C397FBDE002Q36706248-62B6F464-F5D6-4190-BAE3-42527721D4AAQ36748145-0C7D65F8-04CA-41BA-A639-9AD6F8E246C1Q37390601-E247B409-FF5A-465E-A7BD-1D745B5FC074Q37394989-5FFA6176-6638-4AC7-A5DF-9B760C348C56Q37763152-F5169F0D-5591-4E61-8E47-294343A4DC53Q38098512-C45DDB8D-9310-43CF-A5C1-B61CD5C15DB8Q38119168-A22F30F4-3C07-49C4-8D5B-5EE731ABD631Q38167822-87246990-2067-479E-A786-7192FB0895F3Q38202698-07A51A65-EA06-4593-8D9F-DD6352B3881AQ38206716-B64683B6-AA4D-463D-B453-5F41D12EA219Q38248506-9FFD90C0-5497-418B-BC8B-922193635F14Q38660575-187C8F8E-F002-44E5-BFBC-A7CE19BD115EQ39117775-D8951D35-E98F-428E-B5CE-0AE471534D5EQ39201371-D9E29727-B03F-4F60-8085-0237A1B3A90AQ39411779-69A855F7-2860-4E84-945C-54C998155B70Q41777003-E8EA9C69-D905-4BFE-88F5-1226CC23B490Q42084725-D0A6952B-0AF6-4AE7-BF2D-93ED55090543Q43127840-DD4D5B8D-2E6D-452C-816F-E429537AA8AEQ44630513-0ED764FF-53A8-4E04-8A4D-23F2424259CBQ45902882-3BA4687D-F2C1-49C8-B262-DFFEFD42EFBBQ47232325-7992E2E1-0E4E-4F89-9832-38604F30D2A4Q52663431-843FA1D8-FFAC-4197-BD76-158DA84A54CEQ58199045-0415DDA4-9531-49BF-927F-B36DEAB91414
P2860
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@ast
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@en
type
label
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@ast
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@en
prefLabel
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@ast
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@en
P356
P1476
Lipid formulation strategies f ...... in vitro/in vivo case studies.
@en
P2093
Kishor M Wasan
Panayiotis P Constantinides
P304
P356
10.1002/JPS.20780
P407
P577
2007-02-01T00:00:00Z